Journal of Cell Science | Molecular Biology open access journals

The Detection Method of Cell-Derived Exosomes

Jianxiong Hu¹, Kangying Wang⁴, Chengfei Zhao^2,3, Qihong Cai^2,3 and Linghong Pan^2,3

¹Intensive Care Unit (ICU), The Affiliated Hospital of Putian University, China

²Department of Pharmacy, Putian University, China

³Higher Educational Key Laboratory for Pharmaceutical Analysis and Laboratory Medicine of Fujian province, Putian University, China

⁴Department of Clinical Laboratory, The Affiliated Hospital of Putian University, China

Submission: December 18, 2017; Published: February 02, 2018

*Corresponding author: Chengfei Zhao, Department of Pharmacy, Pharmacy and Medical Technology School, Putian University, 1133 Xueyuan Road, Chengxiang District, Putian 351100, PR China; Email: zhaochengfei209@163.com

How to cite this article: Jianxiong Hu, Kangying Wang, Chengfei Zhao, Qihong Cai, Linghong Pan. The Detection Method of Cell-Derived Exosomes. Int J cell Sci & mol biol. 2018; 4(1) : 555626. DOI: 10.19080/IJCSMB.2018.04.555626

Abstract

Exosomes are small extracellular vesicles (30-100nm) from various cells, and have emerged as a promising biomarker of some diseases. Quantitative detection of cell-derived exosome is appealing and challenging. In recent years, many kinds of methods have emerged for the detection and analysis of exosomes, including electrochemical method, microfluidic technology, microarray chip and colorimetric method. We summarize the current detection methods of exosomes and highlight the development direction of detection method for exosomes.

Keywords: Exosomes; Electrochemical biosensors; Microarray chip; Microfluidic platform; Flow immunoassay; Colorimetric method

Introduction

Exosomes were initially reported in 1983 by Johnstone and colleagues while culturing reticulocytes [1]. It is already very clear that exosomes are cell-derived lipid bilayer vesicles that range from 30 to 100nm in diameter [2], are released by many types of cells, such as immune cells and tumor cells [3]. And Exosomes can be found in most bodily fluid, including blood, urine, saliva, amniotic fluid, breast milk, hydrothoracic fluid, and ascitic fluid, as well as in culture medium of most cell types [4]. Exosomes are also an extracellular subset containing microRNAs, messenger RNAs (mRNA), DNA fragments, lipids and proteins for cell communication [5], are transported through the bloodstream and other body fluids [6]. A series of emerging evidence have suggested that exosomes may play an important role in the interaction between tumor cells and their surrounding cells in the tumor microenvironment. However, the detection of exosomes remains challenging and restricts its clinical application. According to the existing literatures, the review summarizes and analyzes the latest detection methods of exosomes, and prospects the detection technology of the exosomes.

Electrochemical Biosensor

Electrochemical biosensors combine the sensitivity of electroanalytical methods with the inherent bioselectivity of the biological component [7]. Wang et al. [8] developed a nanotetrahedron (NTH)-assisted electrochemical aptasensor for direct capture and detection of hepatocellular exosomes, and provided a proof-of-concept for sensitive and efficient quantification of tumor-derived exosomes [8]. The NTH-assisted electrochemical aptasensor combined the strengths of advanced aptamer technology, DNA-based nanostructure and portable electrochemical devices. Aptamer LZH8 with superior binding selectivity on target hepatocarcinoma cells (HepG2) was used for the proposed electrochemical aptasensor. Yadav et al. [9] reported an electrochemical method to directly quantify the breast cancer cell-derived exosomes in cell culture media [9]. The method exhibited an excellent specificity for human epidermal growth factor receptor 2 (+) BT474 cell-derived exosomes (detection limit of 4.7*10⁵ exosomes/μL) with an RSD of < 4.9% (n=3). Zhou et al. [10] developed an electrochemical biosensor based on aptamers specific to exosome transmembrane protein CD63 for the quantitative detection of exosomes [10]. The biosensors functioned well both in “clean” (HEPES Buffer) and “dirty” (DMEM cell culture media containing 10% fetal bovine serum) solutions with a detection limit of 1x106 particles/mL and a linear range extending two orders of magnitude to 1x108 particles/mL. These three studies only detected exosomes in cell culture media, and didn't involve the detection of exosomes in body fluid samples.

Microarray Chip

Microarrays with biomolecules, cells and tissues immobilized on solid substrates are important tools for biological research, including genomics, proteomics, and cell [11]. Ibsen et al. [12] developed an alternating current electrokinetic (ACE) microarray chip device to rapidly isolate and recover glioblastoma exosomes from undiluted human plasma samples [12]. The detection of the exosome specific pattern of external CD63 membrane protein and internal TSG101 protein17 confirms the presence of glioblastoma exosomes among the collected extracellular vesicles by the ACE microarray chip device. The ACE device achieved the direct detection of exosomes in human plasma. Daaboul et al. [15] presented a method based on Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) that allowed multiplexed phenotyping and digital counting of various populations of individual exosomes (>50nm) captured on a microarray-based solid phase chip [13]. The SP-IRIS for the detection of exosomes purified from HEK cell line showed a good correlation for both capture antibodies CD63 and CD81, and detection limits of 5.07x10⁹ particles/mL for CD63 antibody and 3.94x109 particles/mL for CD81 antibody. The imaging method could capture exosomes from a very small volume (20uL) of human cerebrospinal fluid by using antibodies directed against tetraspanins.

Microfluidic Platform

Microfluidic systems can be designed to obtain and process measurements from small volumes of complex fluids with efficiency and speed [14]. Zhao et al. [15] employed a microfluidic ExoSearch chip for diagnosis of ovarian cancer by multiplexed measurement of three exosomal tumor markers (CA-125, EpCAM, CD24) using a training set of plasmas from ovarian cancer patients [15]. The ExoSearch chip combined on-chip continuous-flow mixing and immunomagnetic isolation with an in situ, multiplexed exosome immunoassay, and was applied for ovarian cancer diagnosis via quantifying a panel of tumor markers from exosomes in 20μL of blood plasma within 40min. Zhang et al. [16] developed a microfluidic platform based on a new graphene oxide/polydopamine (GO/PDA) nano-interface for the analysis of circulating exosomes [16]. CD81 mAb served for the capture antibody, and a cocktail of biotinylated mAbs of CD9 and CD81 and EpCAM acted as the detection antibody in the study. The platform was applied to discriminate ovarian cancer patients from healthy controls by the quantitative detection of circulating exosomes directly from 2μL of plasma without sample processing. These two studies provided a feasible microfluidic platform to directly detect exosomes in blood plasma from patients and to facilitate basic investigation of exosomes.

Flow Immunoassay

Lateral flow immunoassay represents a well established and appropriate technology among rapid assays because of its low cost and user-friendliness [17]. Oliveira-Rodriguez et al. developed a novel lateral flow immunoassay (LFIA) for the detection of exosomes based on the use of tetraspanins as targets [18]. The platform was used to detect exosomes purified from different sources, including cell culture supernatants, human plasma and urine, and completed an one-step assay of exosomes in 15 min with detection limit of 8.54x10⁵ exosomes/μL. And the platform selected a blend of anti-CD9 and anti-CD81 as capture antibodies and anti-CD63 labeled with gold nanoparticles as detection antibody. The work achieved a rapid quantification of exosome from different biological samples and provided promising techniques for clinical diagnosis.

Colorimetric Method

Colorimetry is that a well-designed chemical interaction between the analyte and NPs surroundings leads to a change of color allowing the visual detection of the target analyte [19]. Yao et al. [20] reported a visible and colorimetric aptasensor based on DNA-capped single-walled carbon nanotubes for the detection of exosomes, and estimated the linear range from 1.84x106 to 2.21x107 particles/μL with detection limit of 5.2 x10^s particles/ μL [20]. An aptamer specific to exosomes transmembrane protein CD63 was used for the proposed colorimetric aptasensor. The aptasensor was also used to quantify exosomes in serum from breast cancer patients and healthy individuals.

Conclusion and Outlook

The importance of exosomes is self-evident for cancer research. At present, many methods, including electrochemical biosensor, microarray chip, microfluidic platform, flow immunoassay and colorimetric method, provide the detection technology of exosomes. Electrochemical methods afford a sensitive and rapid analysis strategy, but cannot directly detect exosomes in the biological sample. Colorimetric method possesses a simple visual advantage, but is helpless for the direct detection of exosomes in serum. Lateral flow immunoassay is homogeneous and heterogeneous analytical methods which enables the separation of reacted products from unreacted products without any additional precipitation or washing procedure, and provide a promising platform for detecting exosomes. Microarray chip can afford many molecular signatures for cells, tissues and disease states that can be used for disease diagnosis, prediction, prevention and drug discovery, and is more suitable for the analysis and detection of exosomes in complex samples. Microfluidic chip have had a considerable impact on the fields of biomedical diagnostics, and is better to analyze the exosomes in different body fluid. According to the above analysis and summary, the studies of exosomes need to combine various advanced techniques to obtain more comprehensive information of exosomes and to achieve the diagnosis of related diseases in clinical.

Acknowledgement

We gratefully acknowledge the financial support of the Natural Science Foundation of Fujian Province (2017J01547 and 2017J01346), the Key Projects of Science and Technology Plan of Fujian Province (2015Y0030), the Scientific Research Project of Fujian Provincial Colleges and Universities (JK2014045), and the Science and Technology Plan Projects of Putian City (2013S01(2)).